Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against-beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections

Journal of Chemotherapy

Volumn 9, Issue 2, 1997, Pages 89-94

  Nomura, S ^a,b   Hanaki, H ^c   Nagayama, A ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b Juntendo University ^*  (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

complicated urinary tract infection; in vitro antibacterial activity; tazobactam piperacillin; lactamase producing bacteria

Indexed keywords

AMPICILLIN; CEFOPERAZONE; CLAVULANIC ACID; PIPERACILLIN; SULBACTAM; TAZOBACTAM; TICARCILLIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEUS MIRABILIS; PROTEUS VULGARIS; STAPHYLOCOCCUS AUREUS; URINARY TRACT INFECTION;

EID: 0030959007     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1997.9.2.89     Document Type: Article

References (17)

1. Aronoff SC, Jacobs MR, Johenning S, Yamabe S. Comparative activities of the β-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin. Antimicrob Agents Chemother 1984; 26: 580-2.
2. Appelbam PC, Jacobs MR, Spangler SK, Yamabe S. Comparative activity of β-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with β-lactams against β-lactamase-producing anaerobes. Antimicrob Agents Chemother 1986; 30: 789-91.
3. Jacobs MR, Aronoff SC, Johenning S, Yamabe S. Comparative activities of β-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and Pseudomonas. J Antimicrob Chemother 1986; 18: 177-84.
4. Moosdeen F, Williams JD, Yamabe S. Antibacterial characteristics of YTR 830, a sulfone β-lactamase inhibitor, compared with those of clavulanic acid and sulbactam. Antimicrob Agents Chemother 1988; 32: 925-7.
5. Livermore DM, Seetulsingh P. Susceptibility of Escherichia coli isolated with TEM-1 β-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin. J Antimicrob Chemother 1991; 27: 761-7.
6. Higashitani F, Mituhashi S. In vitro and in vivo antibacterial activities or tazobactam-piperacillin. Chemotherapy (Tokyo) 1994; 42 (suppl 2): 1-25.
7. Miyake Y, Miyazaki S, Tsuji A, Kaneko Y, Yamaguchi K, Goto S. In vitro and in vivo antimicrobial activities of tazobactam-piperacillin. Chemotherapy (Tokyo) 1994; 42 (suppl 2): 34-50.
8. Nishino T, Nishida K, Komoto A, Otsuki M. In vitro and in vivo antibacterial activities of tazobactam-piperacillin. Chemotherapy (Tokyo) 1994; 42 (suppl 2): 73-101.
9. Kuck NA, Petersen PJ, Weiss WJ, Testa RT. In vitro and in vivo efficacy of YTR-830H and piperacillin combinations versus β-lactamase-producing bacteria. J Chemother 1989; 1: 155-61.
10. Kumazawa J, Matsumoto T, Kumamoto Y, et al. A comparative study of tazobactam/piperacillin (TAZ/PIPC) vs piperacillin (PIPC) for treatment of complicated urinary tract infections. Nishinihon J Urol 1995; 57: 360-83.
11. Kumazawa J, Matsumoto T, Kumamoto Y, et al. A comparative study of tazobactam/piperacillin (TAZ/PIPC) and sulbactam/cefoperazone (SBT/CPZ) for the treatment of complicated urinary tract infections. Nishinihon J Urol 1995; 57: 339-59.
12. Sanders WE Jr, Sanders CC. Piperacillin/tazobactam: A critical review of the evolving clinical literature. Clin Infect Dis 1996; 22: 107-23.
13. Higashitani F, Mitsuhashi S. In vitro and in vivo efficacy of tazobactam and piperacillin combination and their most effective combination ratio. Chemotherapy (Tokyo) 1994; 42 (suppl 2): 26-33.
14. Thabaut A, Meyran M. Activité in vitro de l'association piperacillin-tazobactam sur 224 souches de Pseudomonas aeruginosa en fonction de la production de β-lactamase. Pathol Biol 1991; 39: 361-6.
15. Uji T, Higashitani F, Nishida K, Hyodo A, Unemi N. Therapeutic efficacy of tazobactam/piperacillin in experimental urinary tract infections with β-lactamase-producing bacteria in mice. Chemotherapy (Tokyo) 1994; 42: 1247-53.
16. Miyake Y, Nishida K, Higashitani F, Uji T, Hyodo A, Ishida N, Unemi N. In vivo antibacterial activity of tazobactam/piperacillin. Chemotherapy (Tokyo) 1994; 42 (suppl 2): 156-63.
17. Yokota T. Current status of beta-lactamase production by clinical isolates: studies in 432 hospitals. Chemotherapy (Tokyo) 1991; 39: 941-952.